Cognition Therapeutics マネジメント
マネジメント 基準チェック /34
Cognition Therapeuticsの CEO はLisa Ricciardiで、 Mar2020年に任命され、 の在任期間は 6.17年です。 の年間総報酬は$ 1.46Mで、 44.6%給与と55.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.56%を直接所有しており、その価値は$ 620.42K 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と6.5年です。
主要情報
Lisa Ricciardi
最高経営責任者
US$1.5m
報酬総額
| CEO給与比率 | 44.60% |
| CEO在任期間 | 6.2yrs |
| CEOの所有権 | 0.6% |
| 経営陣の平均在職期間 | 3.2yrs |
| 取締役会の平均在任期間 | 6.5yrs |
経営陣の近況
Recent updates
分析記事 • Mar 28
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
新しいナラティブ • Mar 26
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?分析記事 • Nov 12
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...分析記事 • Jul 04
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Dec 20
Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Sep 06
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Jul 31
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking Alpha分析記事 • May 22
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Apr 18
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking Alpha分析記事 • Nov 30
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Aug 15
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Mar 17
Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 27
Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27分析記事 • Aug 12
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 05
Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.分析記事 • Mar 19
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$20m |
| Dec 31 2025 | US$1m | US$651k | -US$23m |
| Sep 30 2025 | n/a | n/a | -US$28m |
| Jun 30 2025 | n/a | n/a | -US$33m |
| Mar 31 2025 | n/a | n/a | -US$33m |
| Dec 31 2024 | US$2m | US$629k | -US$34m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$31m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$2m | US$587k | -US$26m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$1m | US$550k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$11m | US$409k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$1m | US$287k | -US$12m |
報酬と市場: Lisaの 総報酬 ($USD 1.46M ) は、 US市場 ($USD 630.36K ) の同規模の企業の平均を上回っています。
報酬と収益: Lisaの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Lisa Ricciardi (65 yo)
6.2yrs
在職期間
US$1,459,635
報酬
Ms. Lisa R. Ricciardi serves as Chief Executive Officer and President at Cognition Therapeutics, Inc. since March 2020 and as Director since March 2019. She serves as an Independent Non-Executive Director...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 6.2yrs | US$1.46m | 0.56% $ 620.4k | |
| Chief Financial Officer | 3yrs | US$866.79k | 0.19% $ 207.4k | |
| Chief Medical Officer | 7.1yrs | US$927.89k | 0.29% $ 322.7k | |
| VP & Head of CMC | 2.8yrs | データなし | データなし | |
| Head of Quality | 2.3yrs | データなし | データなし | |
| Corporate Controller | 3.3yrs | データなし | データなし |
3.2yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: CGTXの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 7.2yrs | US$1.46m | 0.56% $ 620.4k | |
| Independent Director | 4.5yrs | US$68.52k | 0.027% $ 30.6k | |
| Independent Chairman of the Board | 5.8yrs | US$95.02k | 0.016% $ 18.1k | |
| Independent Director | 9.7yrs | US$61.02k | 0.059% $ 65.6k | |
| Member of Medical Advisory Board | 4.3yrs | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.6yrs | US$64.52k | 0.016% $ 18.1k | |
| Independent Director | 10.8yrs | US$59.52k | 0.025% $ 27.8k | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Member of Scientific & Biomarker Advisory Board | 7.5yrs | データなし | データなし | |
| Member of Medical Advisor Board | no data | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし |
6.5yrs
平均在職期間
64.5yo
平均年齢
経験豊富なボード: CGTXの 取締役会 は 経験豊富 であると考えられます ( 6.5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 11:01 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cognition Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |